Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen
Tech optimism hasn’t worn out yet, with the Nasdaq futures pointing to a strong start for these stocks, while the Dow and S&P 500 futures were modestly lower.
FYE25 Outlook
Our non-GAAP outlook for the year ending January 31, 2025 (“FYE25” and “Fiscal 2025”) is as follows:
Revenue: $344 million at the midpoint with a range of +/-2%,
For the second quarter of fiscal 2024 the Company expects total company net sales to be relatively flat to down low single digits compared to $69.4 million in the second quarter of fiscal